Research programme: Rad52 DNA repair and recombination protein inhibitors - Satya Pharma
Alternative Names: RAD52 inhibitors - Satya PharmaLatest Information Update: 28 Aug 2026
At a glance
- Originator Satya Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Rad52 DNA repair and recombination protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for research development in Cancer in India
- 28 Aug 2026 No recent reports of development identified for research development in Non-small-cell-lung-cancer in India
- 28 Aug 2026 No recent reports of development identified for research development in Pancreatic-cancer in India